Duchenne Muscular Dystrophy Therapeutics Market

Executive Summary

Duchenne Muscular Dystrophy Therapeutics Market was valued at US $1,902.76 million in 2021 and is projected to grow at 42.99% CAGR over the forecast period to reach US $16,266.06 million by 2027. Duchenne Muscular Dystrophy Therapeutics Market represented US $972.18 million opportunity over 2019-2021 and estimated to create US $14,363.30 million opportunity in 2027 over 2021.

Duchenne Muscular Dystrophy Therapeutics from Consainsights analyses the Duchenne Muscular Dystrophy Therapeutics Market in the Life Sciences industry over the forecast period to 2027.

Duchenne Muscular Dystrophy Therapeutics research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Duchenne Muscular Dystrophy Therapeutics segmentation includes Treatment Type, End User, Region and Geography.

Based on the Treatment Type, the Duchenne Muscular Dystrophy Therapeutics analysis covers PAIN MANAGEMENT DRUDS, CORTECOSTEROIDS.

In Treatment Type segment, PAIN MANAGEMENT DRUDS segment has highest cagr growth of 37.42%.

Based on the End User, the Duchenne Muscular Dystrophy Therapeutics analysis covers HOSPITALS, CLINICS, HOME CARE SETTINGS.

In End User segment, HOSPITALS segment has highest cagr growth of 37.42%.

Based on the Region, the Duchenne Muscular Dystrophy Therapeutics analysis covers EUROPE, ASIA-PACIFIC, LAMEA.

In Region segment, EUROPE segment has highest cagr growth of 37.42%.

Based on the region, the Duchenne Muscular Dystrophy Therapeutics analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include BRISTOL-MYERS SQUIBB COMPANY, FIBROGEN, INC., ITALFARMACO S.P.A., MARATHON PHARMACEUTICALS, LLC, NS PHARMA, INC, PTC THERAPEUTICS, INC., PFIZER INC., REVERAGEN BIOPHARMA, INC., SANTHERA PHARMACEUTICALS, SAREPTA THERAPEUTICS, INC and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Treatment Type

Introduction

In 2021, PAIN MANAGEMENT DRUDS segment has the highest revenue of US $967.63 million and is expected to grow at CAGR of 37.42% by 2027 PAIN MANAGEMENT DRUDS segment has highest cagr growth of 37.42%.

PAIN MANAGEMENT DRUDS

PAIN MANAGEMENT DRUDS segment was valued at US $473.23 million in 2019 and is projected to grow at 37.42% CAGR over the forecast period to reach US $8,271.93 million by 2027. PAIN MANAGEMENT DRUDS segment represented US $494.39 million opportunity over 2019-2021 and estimated to create US $7,304.31 million opportunity in 2027 over 2021.

CORTECOSTEROIDS

CORTECOSTEROIDS segment was valued at US $457.34 million in 2019 and is projected to grow at 37.42% CAGR over the forecast period to reach US $7,994.12 million by 2027. CORTECOSTEROIDS segment represented US $477.79 million opportunity over 2019-2021 and estimated to create US $7,058.99 million opportunity in 2027 over 2021.

End User

Introduction

In 2021, HOSPITALS segment has the highest revenue of US $1,014.26 million and is expected to grow at CAGR of 37.42% by 2027 HOSPITALS segment has highest cagr growth of 37.42%.

HOSPITALS

HOSPITALS segment was valued at US $496.04 million in 2019 and is projected to grow at 37.42% CAGR over the forecast period to reach US $8,670.56 million by 2027. HOSPITALS segment represented US $518.22 million opportunity over 2019-2021 and estimated to create US $7,656.30 million opportunity in 2027 over 2021.

CLINICS

CLINICS segment was valued at US $285.92 million in 2019 and is projected to grow at 37.42% CAGR over the forecast period to reach US $4,997.81 million by 2027. CLINICS segment represented US $298.71 million opportunity over 2019-2021 and estimated to create US $4,413.18 million opportunity in 2027 over 2021.

HOME CARE SETTINGS

HOME CARE SETTINGS segment was valued at US $148.61 million in 2019 and is projected to grow at 37.42% CAGR over the forecast period to reach US $2,597.69 million by 2027. HOME CARE SETTINGS segment represented US $155.26 million opportunity over 2019-2021 and estimated to create US $2,293.82 million opportunity in 2027 over 2021.

Region

Introduction

In 2021, EUROPE segment has the highest revenue of US $692.09 million and is expected to grow at CAGR of 37.42% by 2027 EUROPE segment has highest cagr growth of 37.42%.

EUROPE

EUROPE segment was valued at US $338.48 million in 2019 and is projected to grow at 37.42% CAGR over the forecast period to reach US $5,916.47 million by 2027. EUROPE segment represented US $353.61 million opportunity over 2019-2021 and estimated to create US $5,224.38 million opportunity in 2027 over 2021.

ASIA-PACIFIC

ASIA-PACIFIC segment was valued at US $335.88 million in 2019 and is projected to grow at 37.42% CAGR over the forecast period to reach US $5,871.06 million by 2027. ASIA-PACIFIC segment represented US $350.90 million opportunity over 2019-2021 and estimated to create US $5,184.28 million opportunity in 2027 over 2021.

LAMEA

LAMEA segment was valued at US $256.21 million in 2019 and is projected to grow at 37.42% CAGR over the forecast period to reach US $4,478.52 million by 2027. LAMEA segment represented US $267.67 million opportunity over 2019-2021 and estimated to create US $3,954.64 million opportunity in 2027 over 2021.